The hard-fought spirit of community mobilisation which informed a successful global fight against the HIV pandemic has been vastly undone by the twisted COVID response engineered by developed nations and Big Pharma
India's rare disease policy sets a Rs. 50 lakh ceiling. Roche's Risdiplam costs Rs. 72 lakhs a year. A generic alternative exists at a fraction of the price, but is tied up in patent litigation. Amidst this, rare disease patients are left to fight their own battles.
The deletion of Section 377 of the Indian Penal Code from the new penal code, the Bharatiya Nyaya Sanhita, has raised a lot of questions. What is the actual impact?
